InflaRx
IFRX
34 hedge funds and large institutions have $414M invested in InflaRx in 2018 Q2 according to their latest regulatory filings, with 9 funds opening new positions, 19 increasing their positions, 4 reducing their positions, and 4 closing their positions.
375% more repeat investments, than reductions
Existing positions increased: 19 | Existing positions reduced: 4
125% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 4
45% more capital invested
Capital invested by funds: $285M → $414M (+$129M)
17% more funds holding
Funds holding: 29 → 34 (+5)
8.5% more ownership
Funds ownership: 42.19% → 50.69% (+8.5%)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RG
Redmile Group
San Francisco,
California
|
+$40.6M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
+$34.2M |
| 3 |
AG
Artal Group
Luxembourg
|
+$13M |
| 4 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$12M |
| 5 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
+$3.05M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCLSI
Bain Capital Life Sciences Investors
Boston,
Massachusetts
|
-$3.81M |
| 2 |
Norges Bank
Oslo,
Norway
|
-$2.6M |
| 3 |
DM
Deerfield Management
New York
|
-$2.55M |
| 4 |
Jennison Associates
New York
|
-$1.86M |
| 5 |
EU
Emory University
Atlanta,
Georgia
|
-$456K |
IFRX Hedge Fund Activity: Q2 2018 in Review
34 of the 4,385 institutional investors tracked by Wall St. Rank reported a position in InflaRx (IFRX) for Q2 2018, worth a combined $414M — up 45% from $285M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new IFRX positions and 4 closed out — a net gain of 5 holders — while 19 added to existing stakes and 4 trimmed.
The largest buyer was Redmile Group, adding an estimated $40.6M. The largest seller was Bain Capital Life Sciences Investors, cutting an estimated $3.81M.
- 34 institutional investors held InflaRx (IFRX) as of Q2 2018, up from 29 in Q1 2018.
- Funds reported $414M of InflaRx stock for Q2 2018, up 45% quarter-over-quarter.
- 9 funds opened new InflaRx positions in Q2 2018 and 4 closed out, a net change of +5 holders.
- The largest InflaRx buyer in Q2 2018 was Redmile Group, an estimated $40.6M added.
- The largest InflaRx seller in Q2 2018 was Bain Capital Life Sciences Investors, an estimated $3.81M sold.
Based on aggregated 13F filings for Q2 2018.